Compare Devon Energy Corp (DVN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Neurocrine Biosciences Inc — how do they compare? Devon Energy Corp trades at $48.26 (market cap $53.81B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Devon Energy Corp is far larger — about 3.7× Neurocrine Biosciences Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DVN | NBIX | |
|---|---|---|
Market Cap | $53.81B | $14.36B |
Volume | 11,556,740 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $52.07 | $185.50 |
52-Week Low | $31.74 | $123.10 |
Typical Hold Time | 136 Days | 23 Days |
Enterprise Value | $64.55B | $14.37B |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.26, up 0.79% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 10.63 and net margin of 16.67%, supported by recent earnings beats. Analyst consensus is strongly bullish with a $62.53 price target, representing 30% upside potential. Recent news highlights activist investor pressure for strategic alternatives including potential sale, while BP shows interest in acquiring Eagle Ford assets.
DVN presents compelling value with attractive valuation metrics and solid profitability. Key opportunities include potential asset sales and Permian Basin strength, while risks involve oil price volatility and execution of strategic initiatives. The stock's current valuation discount to analyst targets suggests significant upside if operational improvements materialize.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
